QyScore® produces a wide range of automated neuroimaging biomarkers to assist physicians making clinical care decisions and monitoring patients over time. QyScore® is FDA-Cleared, CE-Marked and soon expanding into new global markets.

QyScore® also has demonstrated superior performance compared to certain other automated state-of-the-art methods and has been validated against gold-standard manual segmentation.

AI-powered and proprietary neuroimaging software platform, QyScore®, aims to provide physicians, pharma researchers and payers an objective layer of precision when making a CNS disease diagnosis. QyPredict®, for research use only, is being designed to transform what we know about CNS disease
trajectory by combining genomics, biofluids, neuroimaging, cognitive endpoints and measures of activities of daily living to help guide health decisions.